LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

AnaptysBio Inc

Затворен

СекторЗдравеопазване

22.4 -4.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.1

Максимум

22.93

Ключови измерители

By Trading Economics

Приходи

-18M

-39M

Продажби

-15M

28M

EPS

-1.28

Марж на печалбата

-141.619

Служители

136

EBITDA

-24M

-28M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+117.54% upside

Дивиденти

By Dow Jones

Следващи печалби

1.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

57M

670M

Предишно отваряне

26.51

Предишно затваряне

22.4

Настроения в новините

By Acuity

60%

40%

335 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

AnaptysBio Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.06.2025 г., 20:51 ч. UTC

Печалби

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 20:48 ч. UTC

Пазарно говорене

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27.06.2025 г., 19:31 ч. UTC

Пазарно говорене

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27.06.2025 г., 19:19 ч. UTC

Пазарно говорене

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27.06.2025 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27.06.2025 г., 18:39 ч. UTC

Пазарно говорене
Печалби

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27.06.2025 г., 18:18 ч. UTC

Пазарно говорене

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27.06.2025 г., 18:16 ч. UTC

Пазарно говорене

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27.06.2025 г., 17:16 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27.06.2025 г., 17:08 ч. UTC

Печалби

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27.06.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27.06.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

27.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

27.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27.06.2025 г., 15:56 ч. UTC

Пазарно говорене

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

AnaptysBio Inc Прогноза

Ценова цел

By TipRanks

117.54% нагоре

12-месечна прогноза

Среден 50.86 USD  117.54%

Висок 90 USD

Нисък 25 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за AnaptysBio Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

10

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

19.25 / 21.135Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

335 / 380 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.